Session 5: Protein Degraders.

The so-called undruggable space is an exciting area of potential growth for drug development. Undruggable proteins are defined as those unable to be targeted via conventional small molecule drugs. New modalities are being developed to potentially target these proteins.

Trans-Atlantic collaboration to establish a nurse practitioner-program in Switzerland.

Aims: This study was conducted to design, develop and implement an adult gerontology nurse practitioner (AGNP)-track in a Master of Science in Nursing (MSN)- program at a Swiss university of applied science (Swiss UAS) with a minimum of 500 practice hours.

Background: Healthcare delivery models integrating advanced practice nurses (APN) are increasingly important due to demographic needs, public health challenges, and shortage of healthcare professionals. In countries such as Switzerland, nursing has traditionally had a late integration of Bachelor of Science in Nursing (BSN), and MSN have been predominantly taught without practice hours.

The Heart Failure Patient Foundation Position Statement on Research and Patient Involvement.

Background: Heart Failure (HF) is a growing global public health problem affecting approximately 64 million people worldwide.

Objectives: The Heart Failure Patient Foundation developed a position statement to advocate for adult patients with HF to be an active participant in research and for HF leaders to integrate patients throughout the research process.

Methods: A review of the literature and best practices was conducted.

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma.

Cluster of differentiation 47 (CD47) is a transmembrane protein highly expressed in tumor cells that interacts with signal regulatory protein alpha (SIRPα) and triggers a "don't eat me" signal to the macrophage, inhibiting phagocytosis and enabling tumor escape from immunosurveillance. The CD47-SIRPα axis has become an important target for cancer immunotherapy. To date, the advancement of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hematologic toxicity including anemia.

Industry perspective on the nonclinical safety assessment of heterobifunctional degraders.

Targeted protein degraders (TPDs), which act through the ubiquitin proteasome system (UPS), are one of the newest small-molecule drug modalities. Since the initiation of the first clinical trial in 2019, investigating the use of ARV-110 in patients with cancer, the field has rapidly expanded. Recently, some theoretical absorption, distribution, metabolism, and excretion (ADME) and safety challenges have been posed for the modality.